Table 3.
Estimated risk of death or chronic disability per 1 million population resulting from L. loa encephalopathy following mass treatment with Mectizan®, under conditions of: 1) no mass treatment; 2) mass treatment with no risk reduction strategy; and 3) mass treatment using REA, RAPLOA-40, RAPLOA-20, or combined REA/RAPLOA-40 to reduce risk of L. loa encephalopathy. Four scenarios are considered based on high and low prevalence of loiasis and onchocerciasis, respectively (defined in the Appendix - see additional file 1).
| Loiasis Prevalence | High | High | Low | Low |
| Onchocerciasis Prevalence | High | Low | High | Low |
| No Mectizan® treatment | 0 | 0 | 0 | 0 |
| Mectizan® treatment | ||||
| No risk-reduction strategy | 85.1 | 85.1 | 26.0 | 26.0 |
| REA | 5.1 | 3.4 | 0.5 | 0.3 |
| RAPLOA-40 | 12.9 | 12.9 | 2.0 | 2.0 |
| RAPLOA-20 | 5.6 | 5.6 | 0.6 | 0.6 |
| REA/RAPLOA-40 | 12.4 | 11.0 | 2.0 | 1.9 |